Berlin-Based Neurotech Startup Secures Investment for the Development of a Digital Drug to Treat Alzheimer’s Disease

Activating the Memory System of the Brain with Software to Treat Alzheimer’s Disease

04-Nov-2024
Nuuron

Team of Nuuron

Nuuron is developing a fully digital Alzheimer’s therapy based on a proprietary neuromodulation technology. Nuuron’s algorithms produce ultra-high frequency, digital-photonic stimuli that activate the Memory System of Alzheimer’s patients, aiming to improve memory formation and memory recall. This digital disease-modifying therapy uses the retina as interface into the brain and employs advanced VR and AR technologies for stimulation delivery.

Oversubscribed Round and Consortium of Renowned Investors

The Berlin-based neurotech startup Nuuron has raised €3.5 million in an oversubscribed seed financing round. The round is led by High-Tech Gründerfonds (HTGF) and includes investors such as IBB Ventures, caesar., the Business Angel Club Berlin, other business angels and family offices. In addition, Nuuron entered a strategic partnership with RoX Health, a subsidiary of the pharma and diagnostics group Roche.

Clinical Trials with Charité and DZNE – Market Entry in Europe and the U.S.

Nuuron will use this funding for animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and a clinical trial with Alzheimer’s patients at Charité and to advance product development. Additionally, market entry preparations start in Europe and the U.S.

Nuuron Has Hacked the Neural Code of Memory

"Our scientists have succeeded in hacking the neural code of memory, enabling us to develop a digital drug to treat Alzheimer’s Disease. We call it the Memory Pacemaker – an effective therapy, prescribed by doctors and reimbursed by health insurances", Dr. Markus Müschenich, Co-Founder of Nuuron.

A New Therapy Option for 100+ Million Alzheimer’s Patients

Currently, over 55 million people worldwide live with Alzheimer’s Disease and other dementias, a number expected to rise to 139 million by 2050. The market for Alzheimer’s therapies was estimated at USD 5.8 billion in 2023, with a projected increase to USD 11.4 billion by 2032.

Nuuron Demonstrates the Immense Potential of Digital Drugs

"We at RoX Health have supported Nuuron from the very beginning in a strategic collaboration, as we recognized the immense potential of their technology early on. Nuuron’s innovative approach demonstrates the possibilities that digital therapeutics offer and how we can treat complex diseases even more effectively in the future!" Dr. Robert Schnitzler, CEO, RoX Health, Berlin & Head Digital Health Innovation, Roche Pharma AG.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.